Actively Recruiting
Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?
Led by University Hospital, Toulouse · Updated on 2026-05-11
40
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.
CONDITIONS
Official Title
Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years
- Meet clinical criteria for "possible" autoimmune encephalitis with identified antibodies
- Newly diagnosed with symptoms less than 6 months
- No second-line immunosuppressive treatment
- High or mixed TSPO binding affinity phenotype
You will not qualify if you...
- Pregnant women
- Contraindications to MRI
- Known allergic reaction to [18F]-DPA-714
- Legal protection measure
- Paraneoplastic syndrome following immune checkpoint inhibitor therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital
Toulouse, France
Actively Recruiting
Research Team
M
Marie Rafiq, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here